Rontalizumab

Rontalizumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized
Target IFN-α
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 948570-30-7 N
ATC code None
UNII LDO2FIQ61I Y
Chemical data
Formula C6486H9990N1722O2026S44 
Mol. mass 145.9 kDa
 N(what is this?)  (verify)

Rontalizumab is a humanized monoclonal antibody[1] being developed by Genentech.[2] As of November 2009, it is being investigated in a clinical trial or the treatment of systemic lupus erythematosus.[3]

References

  1. ^ WHO Drug Information
  2. ^ Genentech: Rontalizumab (rhuMAb IFN alpha)
  3. ^ ClinicalTrials.gov NCT00962832 A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus (ROSE)
Immune system ("-l(i[m])-")
Human ("-limu-")
Mouse ("-limo-")
Chimeric ("-lixi-")
Humanized ("-lizu-")
immunosuppressive: Aselizumab • Apolizumab • Benralizumab† • Cedelizumab • Certolizumab pegol • Daclizumab • Eculizumab • Efalizumab • Epratuzumab • Erlizumab • Etrolizumab • Fontolizumab • Itolizumab • Mepolizumab • Mogamulizumab • Natalizumab • Ocrelizumab • Omalizumab • Ozoralizumab • Pascolizumab • Pateclizumab • Pexelizumab • PRO 140† • Reslizumab • Rontalizumab • Rovelizumab • Ruplizumab • Samalizumab • Siplizumab • Talizumab • Teplizumab • Tocilizumab • Toralizumab • Tregalizumab • Vatelizumab • Vedolizumab • Visilizumab • TGN1412§
non-immunosuppressive: Ibalizumab†
Chimeric + humanized
("-lixizu-")
Interleukin ("-k(i[n])-")
Human ("-kinu-")
Humanized ("-kizu-", "-kinzu-")
Inflammatory lesions ("-les-")
Mouse ("-leso-")

M: LMC

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug(L3/4)